Literature DB >> 1855278

Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution.

G Ehninger1, B Proksch, H Schmidt, P Waidelich, B Eichel, R Dopfer.   

Abstract

The pharmacokinetics of etoposide following a new method of administration was determined. Undiluted etoposide was given at a dose of 30 mg/kg as part an intensified conditioning regimen prior to bone marrow transplantation. A terminal half-life of 3.4 +/- 0.7 h and a volume of distribution of 15.4 +/- 9.6 l were found (n = 8); the AUC was 764 +/- 302 micrograms h ml-1. As compared with those obtained in other pharmacokinetic studies using etoposide diluted in normal saline, our data reflect full systemic bioavailability and unaltered pharmacokinetics. The application of undiluted etoposide makes the therapy easier and less time-consuming and avoids a high fluid volume and a high saline load.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855278     DOI: 10.1007/bf00685512

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation.

Authors:  H M Lazarus; R J Creger; D Diaz
Journal:  Cancer Treat Rep       Date:  1986-06

2.  [Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models (author's transl)].

Authors:  G Heinzel; R Hammer; M Wolf; F W Koss; G Bozler
Journal:  Arzneimittelforschung       Date:  1977

3.  Pharmacokinetics of high-dose etoposide.

Authors:  E M Newman; J H Doroshow; S J Forman; K G Blume
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

4.  Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.

Authors:  N Schmitz; W Gassmann; M Rister; W Johannson; M Suttorp; F Brix; J J Holthuis; W Heit; B Hertenstein; J Schaub
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

5.  Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation.

Authors:  R J Creger; R M Fox; H M Lazarus
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

6.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Authors:  M L Slevin; P I Clark; S P Joel; S Malik; R J Osborne; W M Gregory; D G Lowe; R H Reznek; P F Wrigley
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

7.  High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia.

Authors:  A R Zander; S Culbert; S Jagannath; G Spitzer; M Keating; N Larry; K Cockerill; J Hester; L Horwitz; L Vellekoop
Journal:  Cancer       Date:  1987-03-15       Impact factor: 6.860

8.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.

Authors:  K G Blume; S J Forman; M R O'Donnell; J H Doroshow; R A Krance; A P Nademanee; D S Snyder; G M Schmidt; J L Fahey; G E Metter
Journal:  Blood       Date:  1987-04       Impact factor: 22.113

9.  Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.

Authors:  K R Hande; P J Wedlund; R M Noone; G R Wilkinson; F A Greco; S N Wolff
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.